Biotech Showdown: Can Upstart Abivax Challenge Pharma Giant AbbVie in Immunology Race?
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Months after the 'Crypto Black Friday' crash, allegations of platform instability and market manipulation continue to dog Binance, sparking fierce debate about trust and power in the digital asset space.
The Producer Price Index jumped 0.5% last month, more than double November's increase, as rising costs for machinery, metals, and travel services pointed to persistent pipeline pressures for consumers.
Bitcoin's rally to near $91,000 this week was abruptly halted as the U.S. dollar found its footing. The shift highlights the cryptocurrency's growing sensitivity to traditional macroeconomic forces and Federal Reserve policy speculation.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
A four-advisor team managing $1 billion in client assets has left Merrill Lynch to join Raymond James' employee channel, underscoring the intensifying competition for top wealth management talent.
The Federal Reserve's decision to hold interest rates steady signals a strategic pause, not an end to its easing cycle. We break down the immediate and future impacts on everything from credit cards to the housing market.
Ameriprise Financial (NYSE: AMP) reported robust fourth-quarter results for 2025, surpassing revenue expectations with a 13.1% year-over-year sales increase to $5.05 billion. Adjusted earnings per share of $10.83 also came in ahead of analyst forecasts.
The business services sector has outperformed, riding a wave of corporate demand for efficiency. But with economic sensitivity looming, we analyze two companies with robust models and one where caution may be warranted.
While large-cap stocks offer stability, their massive scale often limits growth. We analyze one company whose competitive moat continues to widen and two others where valuation and market dynamics suggest caution is warranted.
The healthcare sector has surged 17.4% in six months, outpacing the S&P 500. While demographic trends fuel long-term growth, regulatory hurdles and valuation concerns demand selective investing. We analyze one company built for decades of returns and two where investors should tread carefully.
While lofty price targets can signal opportunity, a closer look reveals that not all consensus forecasts are created equal. We examine one company poised to deliver and two where investor caution may be warranted.
Hershey (HSY) shares are drawing renewed attention from Wall Street as upbeat earnings sentiment converges with the launch of its innovative Jolly Rancher Heat Wave Gummies. While recent momentum is strong, valuation metrics present a complex picture for the iconic confectioner.
Moody's Corporation bolsters its risk analytics arsenal with strategic acquisitions of Numerated Growth Technologies and CAPE Analytics, positioning itself at the center of a private credit market under the regulatory microscope.
LVMH's wine and spirits arm, led by Hennessy, faces a sharp profit decline amid weak U.S. and Chinese demand, while Rémy Cointreau reports a modest rebound in Cognac sales, highlighting a divided market outlook.
With its share price up nearly 40% in a month, Bannerman Energy (ASX:BMN) is drawing intense investor scrutiny ahead of its December quarter report and investor webinar. Analysts weigh whether the uranium developer's rally has outpaced fundamentals.
Netflix shares face pressure as the streaming giant's 2026 revenue guidance signals a significant growth deceleration, even with its advertising business poised to double. Investor concerns are compounded by a potential multi-billion dollar acquisition.
In a bid to attract new entrants to the market, financial services firm SoFi is offering a significant stock bonus of up to $1,000 for opening a self-directed investment account, eliminating traditional barriers like commissions and minimums.
The Australian chemicals company SciDev (ASX:SDV) is showing early signs of a financial transformation, with its return on capital employed turning positive after years of losses. While its current returns still lag the industry average, a significant increase in capital deployment suggests the firm is aggressively reinvesting for growth.